Examples of 'aflibercept' in a sentence
Meaning of "aflibercept"
aflibercept (verb) - Aflibercept is a medication used to treat certain eye conditions, such as wet age-related macular degeneration
Show more definitions
- A fusion protein under development for the treatment of cancer.
How to use "aflibercept" in a sentence
Basic
Advanced
aflibercept
Aflibercept increased blood pressure in normotensive rodents.
It is unknown whether aflibercept is excreted in human milk.
Eylea contains the active substance aflibercept.
Aflibercept administration resulted in a delay in wound healing in rabbits.
There was no effect of age on the pharmacokinetics of free aflibercept.
There are no data on the use of aflibercept in pregnant women.
No studies have been conducted to evaluate carcinogenicity or mutagenicity of aflibercept.
The dosage for aflibercept can be in any amount necessary.
The medicine contains the active substance aflibercept.
Aflibercept is expected to degrade to small peptides and individual amino acids.
Beovu exhibited an overall safety profile comparable to aflibercept.
There are no data regarding the administration of aflibercept in patients with severe hepatic impairment.
Zaltrap is a medicine that contains the active substance aflibercept.
Aflibercept is not an antibody but a fusión protein and thus has a different mode of action.
The active substance is aflibercept.
See also
Aflibercept was more potent than bevacizumab in all CRC models.
No metabolism studies have been conducted with aflibercept since it is a protein.
There are very limited data available for patients with severe renal impairment treated with aflibercept.
There are no data from the use of aflibercept in pregnant women.
No studies have been conducted on the mutagenic or carcinogenic potential of aflibercept.
Aflibercept is commercially available under the trademark EYLEA.
Most findings were considered to be related to the pharmacological activity of aflibercept.
Exemplary fusión proteins include Aflibercept and Denileukin diftitox.
Eylea is a medicine that contains the active substance aflibercept.
High-titre antibody responses to aflibercept were not detected in any patients.
The generic name for Eylea is aflibercept.
The volume of distribution of free aflibercept at steady-state is approximately 8 litres.
The active component of Eylea is aflibercept.
Aflibercept should be suspended for at least 4 weeks prior to elective surgery.
The scientific name is aflibercept.
Aflibercept does not accumulate in the plasma when administered intravitreally every 4 weeks.
Other molecules include aflibercept.
Aflibercept is administered by intravenous infusion at 4mg/kg every two weeks in combination with chemotherapy.
Carcinogenesis and mutagenesis No studies have been conducted to evaluate carcinogenicity or mutagenicity of aflibercept.
Efficacy and security of brolucizumab compared to aflibercept in DIABETIC MACULAR OEDEMA.
In embodiments, the systemic accumulation is reduced compared with that of tocilizumab and / or aflibercept.
In the event of recurrence, despite appropriate anticoagulation, aflibercept treatment should be discontinued.
Aflibercept should be discontinued in patients with compromised wound healing requiring medical intervention see section 4.2.
As a consequence, the company claimed no added benefit for aflibercept.
It can be also administered intravenously immediately after aflibercept administration over a period of about 90 minutes.
Pre-existing hypertension must be adequately controlled before starting aflibercept.
Free aflibercept binds VEGF to form a stable, inert complex.
The vial contains more than the recommended dose of 2 mg aflibercept.
By binding to VEGF and PlGF, aflibercept stops them having an effect.
In some embodiments, the patient is refractory to one dose of aflibercept therapy.
Aflibercept ( VEGF Trap ) is an investigational angiogenesis inhibitor with a unique mechanism of action.
The pre-filled syringe contains more than the recommended dose of 2 mg aflibercept.
Free aflibercept is primarily cleared by binding to endogenous VEGF to form a stable, inactive complex.
If hypertension can not be adequately controlled, treatment with aflibercept should not be initiated.
Aflibercept was also in a phase III trial for hormone-refractory metastatic prostate cancer.
